MedTrace Logo

Ginkgo Biloba Extract for Schizophrenia

NCT01524380 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2016-07-12

No results posted yet for this study

Summary

A double-blind, randomized, placebo-controlled trial of ginkgo biloba extract (Egb-761) as an add-on therapy to risperidone compared to risperidone plus placebo in the treatment of 200 treatment-naive first-episode patients with schizophrenia. The study addresses an immune dysfunction hypothesis of schizophrenia.

Conditions

Interventions

DRUG

Ginkgo biloba extract

400mg/day, twice a day, 10 weeks

DRUG

Placebo

twice a day, 10 weeks

Sponsors & Collaborators

  • Beijing HuiLongGuan Hospital

    lead OTHER

Principal Investigators

  • Xiang Y Zhang, MD/PhD · Beijing HuiLongGuan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2013-06-30
Completion
2013-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01524380 on ClinicalTrials.gov